Hubei Biocause Heilen Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 239.59 million compared to CNY 276.38 million a year ago. Revenue was CNY 240.38 million compared to CNY 276.83 million a year ago.

Net income was CNY 54.4 million compared to CNY 68 million a year ago. Basic earnings per share from continuing operations was CNY 0.1917 compared to CNY 0.3167 a year ago. Diluted earnings per share from continuing operations was CNY 0.1917 compared to CNY 0.3167 a year ago.